What it is
PE-22-28 is a seven-amino-acid peptide cut down from spadin, a peptide its discoverers called "the first natural antidepressant peptide identified." The story has three steps:
- When the receptor sortilin (also called NTSR3) matures, it releases a propeptide — the "PE" in the name.
- In 2010, a CNRS team in Valbonne described spadin, the piece of that propeptide from position 12 to 28, as a blocker of the TREK-1 potassium channel with antidepressant-like effects in mice (Mazella et al., PLoS Biology, PMID 20405001).
- In 2017 that team watched spadin break down in mouse blood, tested the fragments, and found that the shortest one still working was residues 22 to 28 — PE-22-28 (Djillani et al., Frontiers in Pharmacology, PMID 28955242).
The 2017 paper names the peptide by position only; it does not print its letters. PubChem's spadin record (CID 91826106) has the formula C96H142N26O22, which matches the 18-residue chain YAPLPRWSGPIGVSWGLR by our own residue-mass check. Its last seven residues are GVSWGLR, the sequence sellers usually list — our reading, labelled as such.
What the one paper shows
| Test | Result (PMID 28955242) |
|---|---|
| TREK-1 block, human channel in HEK cells | IC50 0.12 nM vs 40–60 nM for spadin; 55.5 ± 4.6% inhibition (13 cells) |
| Shorter fragments | PE 22-27 and PE 22-25 did not significantly inhibit TREK-1 |
| Forced-swim test, mice | Immobility reduced; in a corticosterone model, 98.1 s at 3.0 µg/kg vs 117.4 s for spadin at 100 µg/kg (10 mice per group) |
| Novelty-suppressed feeding, 4 days | Latency to eat reduced |
| Duration of effect | Up to 23 hours vs 7 hours for spadin |
| Brain-cell markers | Neurogenesis after 4 days in mice; more PSD-95 in cultured mouse cortical neurons |
The paper also tested modified versions — biotinylated, methylated, a glycine-to-alanine swap — and reported that several kept their activity while others, such as the palmitoyl and stearic-acid versions, lost most of it.
What is not established
- Any effect in people. No human study is published, and ClinicalTrials.gov lists none for PE-22-28 or spadin (2026-11-12).
- Memory, focus or "nootropic" effects. The paper measured depression-like behaviour, not cognition.
- Safety. The paper reports no toxicology, and none is indexed elsewhere.
- Replication. Every finding comes from the group that designed the peptide; PubMed indexes one paper that names PE-22-28.
- How it reaches the brain in people. The mice received it by injection into the abdomen.
Where it stands
- Approved: nowhere; the US drug databases return nothing for it.
- Sold as: a research peptide marketed for mood and focus; this library does not review products.
- Research record: one PubMed paper (2017); spadin 83 records; no registered trial (2026-11-12).
Related reading
The peptides most often sold beside it for focus have longer records: Selank and Semax, both registered medicines in Russia, and noopept, a modified dipeptide designed in Moscow. Dihexa shares PE-22-28's position as a compound known mostly from its developers' animal work. How the library judges that kind of evidence across the class is set out in the focus and mood overview.
